Lexicon Pharmaceuticals
  • Home
  • Contact Us
  • Site Map
  • About Us
    • About Us Home
    • Management Team
    • Board of Directors
    • Development Team
    • Locations
    • Contact Us
    • History
  • Pipeline
    • Drug Pipeline Home
    • Our Goal
    • Therapeutic Areas
    • Drug Development Team
    • Clinical Trials
    • Publications
  • Discovery
    • Discovery Home
    • Discovery Process
    • Technology
    • Genome5000
    • Medicinal Chemistry
    • Patents
    • Academic Access
    • Technology Licensing
    • Scientific Publications
  • Alliances
    • Alliances Home
    • Current Alliances
    • Technology Licensing
  • Careers
    • Careers Home
    • Opportunities
    • Our Culture
    • Benefits
    • Community Involvement
    • The Woodlands
    • Princeton
    • Awards and Recognition
  • News
    • News Home
    • Media Inquiries
  • Investors
    • Investors Home
    • Media
    • Events
    • Stock Quote
    • SEC Filings
    • Annual Reports
    • Corporate Governance
    • Request Information
Lexicon Banner
  • News Home
  • Media Inquiries
Subscribe
Press Releases
Filter     Display # 
09/13/2011 LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
09/13/2011 Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
09/06/2011 Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
08/30/2011 Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
08/11/2011 Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
08/10/2011 Lexicon Announces Publication of Results from the Phase 2 Trial of LX1031 in Patients with Irritable Bowel Syndrome in Journal of Gastroenterology
08/09/2011 Phase 2 Trial of Lexicon’s LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
08/08/2011 Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
08/04/2011 Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2011 Financial Results
07/28/2011 Lexicon’s IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
 
«StartPrev12345678910NextEnd»
Page 2 of 41
  • About Us
  • Pipeline
  • Discovery
  • Alliances
  • Careers
  • News
  • Investors
  • Terms Of Use

Copyright © 2009, Lexicon Pharmaceuticals, Inc. All rights reserved.